Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Novel radiotracer identifies biomarker for triple-negative breast cancer
2.
Higher Binge Drinking Rates Linked to New Cannabis Laws.
3.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
4.
Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival
5.
ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?
1.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
2.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
3.
Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth
4.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
5.
The Danger of Methemoglobinemia and How to Prevent It
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
5.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge